OnKure Therapeutics president and CEO Saccomano sells $258 in stock

Nicholas A. Saccomano, President and CEO of OnKure Therapeutics, Inc., sold 87 shares of the company's Class A Common Stock on September 21, 2026, at a weighted average price of $2.9742 per share, totaling $258. This transaction was an automatic sale to cover tax withholding obligations related to the vesting of restricted stock units under the Issuer's 2023 RSU Equity Incentive Plan.

Despite OnKure's stock trading at $2.90, down 27% over the past six months, the company holds more cash than debt on its balance sheet, with liquid assets exceeding short-term obligations. Additionally, H.C. Wainwright adjusted its price target for OnKure Therapeutics to $21 from $27, maintaining a Buy rating, following the presentation of preclinical data for its pan-mutant PI3Kα inhibitors, OKI-345 and OKI-355, which showed greater cellular selectivity compared to competitors.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.